BlackRock, Inc. 13D and 13G filings for Ovid Therapeutics Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2025-07-17 8:12 pm Sale | 2025-06-30 | 13G | Ovid Therapeutics Inc. OVID | BlackRock Inc. BLK | 1,369,010 1.900% | -2,950,908 (-68.31%) | Filing |
| 2024-01-29 5:25 pm Purchase | 2023-12-31 | 13G | Ovid Therapeutics Inc. OVID | BlackRock Inc. BLK | 4,319,918 6.100% | 3,117,188 (+259.18%) | Filing |
| 2021-07-12 08:29 am Sale | 2021-06-30 | 13G | Ovid Therapeutics Inc. OVID | BlackRock Inc. BLK | 1,202,730 1.800% | -2,209,003 (-64.75%) | Filing |
| 2021-02-02 3:13 pm Purchase | 2020-12-31 | 13G | Ovid Therapeutics Inc. OVID | BlackRock Inc. BLK | 3,411,733 5.400% | 2,756,291 (+420.52%) | Filing |